Raloxifene and Fulvestrant Exert Antioxidant, Anti-Inflammatory, and Antiapoptotic Action Against Haloperidol-Induced Tardive Dyskinesia in Rats via Activation of the GPER1/PI3k/Akt/Nrf2/HO-1 Signaling Pathways
Shubham Upadhayay
Department of Pharmacology, Central University of Punjab, Ghudda, Bhatinda, Punjab, India
Search for more papers by this authorDivya Soni
Department of Pharmacology, Central University of Punjab, Ghudda, Bhatinda, Punjab, India
Search for more papers by this authorCorresponding Author
Puneet Kumar
Department of Pharmacology, Central University of Punjab, Ghudda, Bhatinda, Punjab, India
Correspondence: Puneet Kumar ([email protected]; [email protected])
Search for more papers by this authorShubham Upadhayay
Department of Pharmacology, Central University of Punjab, Ghudda, Bhatinda, Punjab, India
Search for more papers by this authorDivya Soni
Department of Pharmacology, Central University of Punjab, Ghudda, Bhatinda, Punjab, India
Search for more papers by this authorCorresponding Author
Puneet Kumar
Department of Pharmacology, Central University of Punjab, Ghudda, Bhatinda, Punjab, India
Correspondence: Puneet Kumar ([email protected]; [email protected])
Search for more papers by this authorABSTRACT
Tardive Dyskinesia (TD) is a pathological condition mainly arises due to supersensitivity of dopaminergic D2 receptors is often caused by long-term administration of antipsychotic medication that leads to involuntary hyperkinetic movement. Till now, there is no permanent treatment available to cure TD. The present study aimed to investigate the neuroprotective effect of raloxifene and fulvestrant, a selective estrogen receptor modulator (SERM), against haloperidol-induced TD in rats. Our study is focused on evaluating the effect of raloxifene and fulvestrant on alteration in behavior, biochemical, apoptosis, neuroinflammation, Immunohistochemistry, and western blot analysis expression in TD rats. In haloperidol (1 mg/kg) treated rats, administration of raloxifene (5 & 10 mg/kg) and fulvestrant (5 & 10 mg/kg) dose dependently improved the locomotor activity, motor co-ordination, neuromuscular strength and decreased Vacuous Chewing Movements (VCMs), Tongue Protrusion (TP), Facial Jerking (FJ). Whereas administration of raloxifene and fulvestrant along with letrozole a nonselective antagonist of GPER1 reduced the effect of raloxifene and fulvestrant. Consequently, raloxifene and fulvestrant reduced oxidative insults (MDA and GSH), caspases level (Caspase 3 and 9), and inflammatory markers (TNF-α, IL-1β, and IL-6), in rats injected with haloperidol. Furthermore, raloxifene and fulvestrant treatment upregulates the expression of GPER1/PI3k/Akt/Nrf2/HO-1 signaling pathway in TD rats; these pathways may be responsible for the reduction in oxidative stress, neuroinflammation, and apoptosis. Meanwhile, treatment of letrozole with raloxifene and fulvestrant substantially downregulated the expression of these proteins, suggesting that raloxifene and fulvestrant exert its effect via GPER1 signaling pathway. The study concludes that raloxifene and fulvestrant have antioxidant, anti-inflammatory, antiapoptotic, and neuroprotective properties suggesting that they could be used in the management of neurological disorders, including TD.
Conflicts of Interest
All authors declare no conflict of interest concerning this manuscript.
Open Research
Data Availability Statement
The data will be made available on request.
References
- 1K. M. Ward and L. Citrome, “Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism Vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management,” Neurology and Therapy 7 (2018): 233–248.
- 2K. Uludag, D. M. Wang, C. Goodman, D. C. Chen, L. Wang, and X. Zhang, “Prevalence, Clinical Correlates and Risk Factors Associated With Tardive Dyskinesia in Chinese Patients With Schizophrenia,” Asian Journal of Psychiatry 66 (2021): 102877.
- 3K. Stegmayer, S. Walther, and P. van Harten, “Tardive Dyskinesia Associated With Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies,” CNS Drugs 32, no. 2 (2018): 135–147.
- 4M. Zivković, A. Mihaljević-Peles, N. Bozina, et al., “The Association Study of Polymorphisms in DAT, DRD2, and Comt Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol,” Journal of Clinical Psychopharmacology 33, no. 5 (2013): 593–599.
- 5H. Y. Meltzer, “Update on Typical and Atypical Antipsychotic Drugs,” Annual Review of Medicine 64, no. 1 (2013): 393–406.
- 6N. G. Yedke, S. Upadhayay, R. Singh, S. Jamwal, S. F. Ahmad, and P. Kumar, “Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-Like Behavioral and Neurochemical Alteration In Experimental Rats,” Biomolecules 13, no. 11 (2023): 1667.
- 7M.-H. Wang, C.-C. Yang, H.-C. Tseng, C.-H. Fang, Y.-W. Lin, and H.-S. Soung, “Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia,” Neurotoxicity Research 39 (2021): 774–786.
- 8H.-C. Tseng, M.-H. Wang, C.-H. Fang, Y.-W. Lin, and H.-S. Soung, “Involvement of Antioxidant and Prevention of Mitochondrial Dysfunction, Anti-Neuroinflammatory Effect and Anti-Apoptotic Effect: Betaine Ameliorates Haloperidol-Induced Orofacial Dyskinesia in Rats,” Brain Sciences 13, no. 7 (2023): 1064.
- 9A. Starek, “Estrogens and Organochlorine Xenoestrogens and Breast Cancer Risk,” International Journal of Occupational Medicine and Environmental Health 16, no. 2 (2003): 113–124.
- 10L. Veenman, “Raloxifene as Treatment for Various Types of Brain Injuries and Neurodegenerative Diseases: A Good Start,” International Journal of Molecular Sciences 21, no. 20 (2020): 7586.
- 11B. Olde and L. M. F. Leeb-Lundberg, “GPR30/GPER1: Searching for a Role in Estrogen Physiology,” Trends in Endocrinology & Metabolism 20, no. 8 (2009): 409–416.
- 12S. Upadhayay, R. Gupta, S. Singh, M. Mundkar, G. Singh, and P. Kumar, “Involvement of the G-Protein-Coupled Estrogen Receptor-1 (GPER) Signaling Pathway in Neurodegenerative Disorders: A Review,” Cellular and Molecular Neurobiology 43, no. 5 (2023): 1833–1847.
- 13M. D. Moen and G. M. Keating, “Raloxifene: A Review of Its Use in the Prevention of Invasive Breast Cancer,” Drugs 68 (2008): 2059–2083.
- 14S. Sammons, N. S. Kornblum, and K. L. Blackwell, “Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer,” Targeted Oncology 14 (2019): 1–12.
- 15K. O'Neill, S. Chen, and R. D. Brinton, “Impact of the Selective Estrogen Receptor Modulator, Raloxifene, on Neuronal Survival and Outgrowth Following Toxic Insults Associated With Aging and Alzheimer's Disease,” Experimental Neurology 185, no. 1 (2004): 63–80.
- 16L. Zhao, K. O'Neill, and R. D. Brinton, “Estrogenic Agonist Activity of ICI 182,780 (Faslodex) in Hippocampal Neurons: Implications for Basic Science Understanding of Estrogen Signaling and Development of Estrogen Modulators With a Dual Therapeutic Profile,” Journal of Pharmacology and Experimental Therapeutics 319, no. 3 (2006): 1124–1132.
- 17A.-A. Poirier, M. Côté, M. Bourque, M. Morissette, T. Di Paolo, and D. Soulet, “Neuroprotective and Immunomodulatory Effects of Raloxifene in the Myenteric Plexus of a Mouse Model of Parkinson's Disease,” Neurobiology of Aging 48 (2016): 61–71.
- 18Z. Liu, Y. Wang, W. Qin, et al., “Raloxifene Alleviates amyloid-β-induced Cytotoxicity in HT22 Neuronal Cells via Inhibiting Oligomeric and Fibrillar Species Formation,” Journal of Biochemical and Molecular Toxicology 33, no. 11 (2019): 1–8.
10.1002/jbt.22395 Google Scholar
- 19F. H. Pottoo, N. Tabassum, M. N. Javed, et al., “Raloxifene Potentiates the Effect of Fluoxetine Against Maximal Electroshock Induced Seizures in Mice,” European Journal of Pharmaceutical Sciences 146 (2020): 105261.
- 20G. M. MenezesdaSilva, E. C. A. Veiga, M. J. Simões, et al, “Effects of Estrogen and Raloxifene on Synaptic Density in the Hippocampal CA1 Region of Ovariectomized Rats,” Clinics 78 (2024): 1–6.
- 21L. Wang, J. Liu, J. Xu, W. Zhang, and R. Wang, “Coupling of GPR30 Mediated Neurogenesis and Protection With Astroglial Aromatase-STAT3 Signaling in Rat Hippocampus After Global Cerebral Ischemia,” Molecular and Cellular Endocrinology 535 (2021): 111394-12.
- 22S. Yamamoto, T. Yamashita, M. Ito, et al., “New Pharmacological Effect of Fulvestrant to Prevent Oxaliplatin-Induced Neurodegeneration and Mechanical Allodynia in Rats,” International Journal of Cancer 145, no. 8 (2019): 2107–2113.
- 23M. Bourque, M. Morissette, and T. Di Paolo, “Raloxifene Activates G Protein-Coupled Estrogen Receptor 1/Akt Signaling to Protect Dopamine Neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mice,” Neurobiology of Aging 35, no. 10 (2014): 2347–2356.
- 24A. Kadir, J. Singh, V. Rahi, and P. Kumar, “Berberine Ameliorate Haloperidol and 3-Nitropropionic Acid-Induced Neurotoxicity in Rats,” Neurochemical Research 47, no. 11 (2022): 3285–3297.
- 25S. Upadhayay, S. Mehan, A. Prajapati, et al., “Nrf2/HO-1 Signaling Stimulation Through Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) Provides Neuroprotection in Ethidium Bromide-Induced Experimental Model of Multiple Sclerosis,” Genes 13, no. 8 (2022): 1324.
- 26K. S. Thakur, A. Prakash, R. Bisht, and P. K. Bansal, “Beneficial Effect of Candesartan and Lisinopril Against Haloperidol-Induced Tardive Dyskinesia in Rat,” Journal of the Renin-Angiotensin-Aldosterone System 16, no. 4 (2015): 917–929.
- 27S. Datta, S. Jamwal, R. Deshmukh, and P. Kumar, “Beneficial Effects of Lycopene Against Haloperidol Induced Orofacial Dyskinesia in Rats: Possible Neurotransmitters and Neuroinflammation Modulation,” European Journal of Pharmacology 771 (2016): 229–235.
- 28R. Gupta, D. Soni, S. Upadhayay, M. Dhureja, and P. Kumar, “Impact of Noscapine on Halting the Progression of Pentylenetetrazole Induced Kindling Epilepsy in Mice,” Clinical and Experimental Pharmacology and Physiology 50, no. 12 (2023): 984–991.
- 29E. Minj, S. Upadhayay, and S. Mehan, “Nrf2/HO-1 Signaling Activator Acetyl-11-keto-beta Boswellic Acid (AKBA)-Mediated Neuroprotection in Methyl Mercury-Induced Experimental Model of ALS,” Neurochemical Research 46, no. 11 (2021): 2867–2884.
- 30R. Arthur, U. Navik, and P. Kumar, “Artemisinin Ameliorates the Neurotoxic Effect of 3-Nitropropionic Acid: A Possible Involvement of the ERK/BDNF/Nrf2/HO-1 Signaling Pathway,” Molecular Neurobiology 62, no. 1 (2025): 3583–3600.
- 31M. E. Noureldeen, N. N. Shahin, H. A. A. Amin, M. M. El-Sawalhi, and H. R. Ghaiad, “Parthenolide Ameliorates 3-nitropropionic Acid-Induced Huntington's Disease-Like Aberrations via Modulating NLRP3 Inflammasome, Reducing Microglial Activation and Inducing Astrocyte Shifting,” Molecular Medicine 30, no. 1 (2024): 158.
- 32P. Thomas, Y. Pang, E. J. Filardo, and J. Dong, “Identity of An Estrogen Membrane Receptor Coupled to a G Protein in Human Breast Cancer Cells,” Endocrinology 146, no. 2 (2005): 624–632.
- 33C. Roque, J. Mendes-Oliveira, C. Duarte-Chendo, and G. Baltazar, “The Role of G Protein-Coupled Estrogen Receptor 1 on Neurological Disorders,” Frontiers in Neuroendocrinology 55 (2019): 100786-13.
- 34J. Correa, S. Ronchetti, F. Labombarda, A. F. De Nicola, and L. Pietranera, “Activation of the G Protein-Coupled Estrogen Receptor (GPER) Increases Neurogenesis and Ameliorates Neuroinflammation in the Hippocampus of Male Spontaneously Hypertensive Rats,” Cellular and Molecular Neurobiology 40, no. 5 (2020): 711–723.
- 35F. Zhou, H. Dong, Y. Liu, et al., “Raloxifene, a Promising Estrogen Replacement, Limits TDP-25 Cell Death by Enhancing Autophagy and Suppressing Apoptosis,” Brain Research Bulletin 140 (2018): 281–290.
- 36M. Zhang, Z.-F. Hu, X.-L. Dong, and W.-F. Chen, “Epimedin B Exerts Neuroprotective Effect Against MPTP-Induced Mouse Model of Parkinson's Disease: GPER as a Potential Target,” Biomedicine & Pharmacotherapy = Biomedecine & pharmacotherapie 156 (2022): 113955-12.
- 37J. A. Kajero, S. Seedat, J. U. Ohaeri, A. Akindele, and O. Aina, “The Effects of Cannabidiol on Behavioural and Oxidative Stress Parameters Induced by Prolonged Haloperidol Administration,” Acta Neuropsychiatrica 36, no. 5 (2022): 265–275.
- 38D. Soni, S. Upadhayay, M. Dhureja, R. Arthur, and P. Kumar, “Crosstalk Between Gut–Brain Axis: Unveiling the Mysteries of Gut ROS in Progression of Parkinson's Disease,” Inflammopharmacology 32, no. 5 (2024): 2921–2941.
- 39P. Shoae-Hagh, B. M. Razavi, H. R. Sadeghnia, S. Mehri, G. Karimi, and H. Hosseinzadeh, “Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Rats,” Molecular Neurobiology 62, no. 4 (2025): 5156–5182.
- 40J. Peng, J. He, X. Hu, and Y. Xia, “GPR30 Alleviated Subarachnoid Hemorrhage-Induced Blood-Brain Barrier Dysfunction by Activating the PI3K/Akt and Nrf2/HO-1 Pathways,” American Journal of Physiology-Cell Physiology 327, no. 1 (2024): C65–C73.
- 41S. Datta, S. Jamwal, R. Deshmukh, and P. Kumar, “Beneficial Effects of Lycopene Against Haloperidol Induced Orofacial Dyskinesia in Rats: Possible Neurotransmitters and Neuroinflammation Modulation,” European Journal of Pharmacology 771 (2016): 229–235.
- 42M. Côté, M. Bourque, A. A. Poirier, et al., “GPER1-mediated Immunomodulation and Neuroprotection in the Myenteric Plexus of a Mouse Model of Parkinson's Disease,” Neurobiology of Disease 82 (2015): 99–113.
- 43B. Yazğan, Y. Yazğan, İ. S. Övey, and M. Nazıroğlu, “Raloxifene and Tamoxifen Reduce PARP Activity, Cytokine and Oxidative Stress Levels in the Brain and Blood of Ovariectomized Rats,” Journal of Molecular Neuroscience 60, no. 2 (2016): 214–222.
- 44Y. Zhang, T. Sun, Z. Zhao, et al., “Activation of GPR30 Ameliorates Cerebral Ischemia-Reperfusion Injury by Suppressing Ferroptosis Through Nrf2/GPX4 Signaling Pathway,” NeuroMolecular Medicine 26, no. 1 (2024): 33.
- 45Y. Liang, W. Fu, Y. Tang, et al., “Selective Activation of G Protein-Coupled Estrogen Receptor 1 (GPER1) Reduces ER Stress and Pyroptosis via AMPK Signaling Pathway in Experimental Subarachnoid Hemorrhage,” Molecular Neurobiology 62, no. 1 (2024): 871–884.
- 46Z. Feng, C. Wang, Y. Jin, Q. Meng, J. Wu, and H. Sun, “Kaempferol-Induced GPER Upregulation Attenuates Atherosclerosis via the PI3K/AKT/Nrf2 Pathway,” Pharmaceutical Biology 59, no. 1 (2021): 1104–1114.
- 47Z. F. Wang, Z. Y. Pan, C. S. Xu, and Z. Q. Li, “Activation of G-Protein Coupled Estrogen Receptor 1 Improves Early-Onset Cognitive Impairment via PI3K/Akt Pathway in Rats With Traumatic Brain Injury,” Biochemical and Biophysical Research Communications 482, no. 4 (2017): 948–953.
